Physician profile
Robert D Lafsky
NPI 1336124163
$6,035.06
in general payments reported to CMS, 2019-2025
35 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $316 · 2021: $698 · 2022: $874 · 2023: $998 · 2024: $1,220 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,584.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $935.38 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $573.16 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $511.39 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $444.74 | 2019-2025 | |
| Celgene Corporation | $334.78 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $304.88 | 2021-2025 | Sucraid |
| Ardelyx, INC. | $272.25 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $143.87 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $118.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $108.30 | 2022-2025 | |
| Lilly USA, LLC | $97.23 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $91.33 | 2024-2025 | Iqirvo, Bylvay |
| Alnylam Pharmaceuticals INC. | $90.67 | 2022-2024 | Givlaari |
| Daiichi Sankyo INC. | $88.74 | 2020-2025 | Injectafer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $83.06 | 2024 | Idacio |
| Regeneron Healthcare Solutions, INC. | $60.30 | 2022-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $48.35 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $46.44 | 2024 | Voquezna |
| Organon LLC | $46.18 | 2024-2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $40.98 | 2021-2023 | |
| Allergan, INC. | $40.61 | 2019 | |
| Covidien LP | $39.01 | 2019 | |
| Aimmune Therapeutics, INC. | $34.99 | 2024 | |
| Intercept Pharmaceuticals, INC. | $33.47 | 2024-2025 | |
| Celltrion USA INC. | $33.43 | 2025 | Vegzelma |
| Genzyme Corporation | $29.63 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.20 | 2024 | Cyltezo |
| Novo Nordisk INC | $21.49 | 2025 | Wegovy |
| Capsovision, INC. | $21.05 | 2024 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $18.12 | 2022 | |
| Alfasigma USA, INC. | $17.54 | 2020 | |
| Sandoz INC. | $16.91 | 2025 | |
| Redhill Biopharma INC. | $16.29 | 2021 | |
| Shionogi INC | $15.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lafsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.